Aliskiren dosage forms and strengths: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Aliskiren}} {{CMG}}; {{AE}} {{SS}} ==Dosage Forms and Strengths== ===2.1 Hypertension=== The usual recommended starting dose of Tekturna is 150 mg once dail...")
 
(Redirected page to Aliskiren#How Supplied)
 
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Aliskiren#How Supplied]]
{{Aliskiren}}
{{CMG}}; {{AE}} {{SS}}
 
==Dosage Forms and Strengths==
 
===2.1    Hypertension===
 
The usual recommended starting dose of Tekturna is 150 mg once daily. In patients whose blood pressure is not adequately controlled, the daily dose may be increased to 300 mg. Doses above 300 mg did not give an increased blood pressure response but resulted in an increased rate of diarrhea. The antihypertensive effect of a given dose is substantially attained (85-90%) by 2 weeks.
 
===2.2    Use with Other Antihypertensives===
 
Tekturna may be administered with some other antihypertensive agents. In diabetics, do not use in combination with [[angiotensin receptor blockers]] (ARBs) or [[angiotensin]]converting enzyme inhibitors (ACEIs) [see Contraindications (4)]. Concomitant use of aliskiren with an ARB or ACEI is not recommended in patients with GFR <60 ml/min [see Warnings and Precautions (5.2)]. Most exposure to date is with [[diuretics]], an [[angiotensin]]receptor blocker (valsartan) or a [[calcium channel blocker]] (amlodipine). Aliskiren used together with these drugs has a greater effect at their maximum recommended doses than either drug alone. It is not known whether additive effects are present when Tekturna is used with angiotensin-converting enzyme inhibitors (ACEIs) or [[beta blockers]] (BB).
 
===2.3    Relationship to Meals===
 
Patients should establish a routine pattern for taking Tekturna with regard to meals. High fat meals decrease absorption substantially [see Clinical Pharmacology (12.3)].<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = TEKTURNA (ALISKIREN HEMIFUMARATE) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=833c7a0b-5f64-4363-94d5-9a179049113a | publisher =  | date =  | accessdate = 25 February 2014 }}</ref>
==References==
{{reflist|2}}
 
{{Agents acting on the renin-[[angiotensin]]system}}
 
[[Category:Renin inhibitors]]
[[Category:Phenol ethers]]
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]

Latest revision as of 15:18, 21 July 2014